Health Care Equipment

Wego Ortho

Wego Ortho released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 296.33 M, actual EPS CNY 0.11

Wego Ortho to Release FY2026 Q1 Earnings on April 30 After-Market (BJT)

Weigao Orthopaedic to Release FY2025 Earnings on March 28 Pre-Market (BJT), Forecast Revenue CNY 1.528 B, EPS CNY 0.68

Wego Ortho released FY2025 Annual Earnings on February 27 Pre-Market (BJT), Actual Revenue: CNY 1.523 B (Forecast: CNY 1.528 B), Actual EPS: CNY 0.67 (Forecast: CNY 0.68)

Wego Ortho released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue CNY 416.53 M, actual EPS CNY 0.1503

Weigao Orthopaedic FY2025 Q3 Earnings Release on October 31 After-Market BJT

Weigao Orthopaedic released FY2025 Q3 earnings on October 13 After-Market (BJT), actual revenue CNY 365.34 M, actual EPS CNY 0.1698

Weigao Orthopaedic released FY2025 9 Months Earnings on October 13 After-Market (BJT), actual revenue CNY 1.106 B, actual EPS CNY 0.5182

Weigao Orthopaedic released FY2025 Q2 earnings on August 27 During-Market (BJT), actual revenue CNY 450.73 M, actual EPS CNY 0.2184

Weigao Orthopaedic released FY2025 Semi-Annual Earnings on August 27 During-Market (BJT), actual revenue CNY 740.92 M, actual EPS CNY 0.35

Weigao Orthopaedic FY2025 Semi-Annual Earnings Release on August 28, 2025 (BJT)

Weigao Bone Tech Q1 2025 Report: Revenue Down, Net Profit Up

Weigao Orthopaedic released FY2025 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 290.19 M, actual EPS CNY 0.13

Weigao Orthopaedic to Release FY2025 Q1 Earnings on April 30 After-Market BJT

Weigao Orthopedics Announces 2025 Restricted Stock Incentive Plan to Grant 7.2 Million Shares

Weigao Orthopedics Achieves Revenue of 1.453 Billion Yuan and Net Profit of 224 Million Yuan in 2024

Weigao Orthopaedic to Release FY2024 Earnings on March 27, 2025 (BJT), Forecast Revenue 1.474 B CNY, EPS 0.55 CNY

Weigao Orthopaedic released FY2024 earnings on February 27, 2025 (BJT), actual revenue CNY 1.453 B (forecast CNY 1.474 B), actual EPS CNY 0.56 (forecast CNY 0.55)

Weigao Orthopaedic released FY2024 Q4 earnings on February 27, 2025 (BJT) with actual revenue of CNY 369.44 M and EPS of CNY 0.1501

Weigao Orthopedics Expects Net Profit Growth of 78.07% to 113.68% for 2024

01066

688161

159883

159898

562600

Shandong Weigao Group Medical Polymer Co, a Hong Kong-listed medical device maker, announced that its orthopaedic subsidiary has disclosed information on the Shanghai Stock Exchange, complying with listing rules in both PRC and Hong Kong. This move emphasizes the company's commitment to regulatory transparency and consistent communication with investors across markets. The latest analyst rating for the stock (HK:1066) is a Hold with a price target of HK$5.50, and the company has a market cap of HK$20.08B.

Tip Ranks

WEIGAO GROUP

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

Weigao Group Flags Orthopaedic Unit Disclosure on Shanghai Exchange

CurveBeam AI Ltd. has received orders for five imaging devices in Q2 FY26, including four HiRise systems, indicating increased demand for its orthopedic imaging solutions. The company is advancing its partnership with WEGO Orthopaedics in China, leading to a A$4.0 million investment. Additionally, CurveBeam submitted an FDA application for a bone mineral density module, aiming for clearance by mid-2026. The latest analyst rating for CurveBeam AI stock is a Hold with a price target of A$0.15.

Beamr Imaging

CurveBeam AI Secures Device Orders, Advances China Partnership and FDA Filing in Q2 FY26

According to the Zhitong Finance APP, WEIGAO GROUP released its performance for WeigaoOrthopaedic in the first half of 2025, with operating revenue of 741 million yuan (RMB, the same below), a year-on-year decrease of 1.28%; net profit attributable to shareholders of the listed company was 142 million yuan, a year-on-year increase of 52.43%; basic earnings per share were 0.35 yuan

Zhitong

WEIGAO GROUP: WeigaoOrthopaedic's net profit attributable to the parent company in the first half of the year was 142 million yuan, a year-on-year increase of 52.43%

603233

688621

600993

688185

06185

601567

Bank of China International released a research report stating that the Medical Insurance Bureau has launched the 11th batch of centralized procurement, emphasizing the principles of "stabilizing clinical practices, ensuring quality, preventing collusion, and resisting involution," while optimizing procurement rules. This centralized procurement will no longer simply reference the lowest price; companies with the lowest bids are required to publicly explain the rationale and commit to not quoting below cost. It is expected that as price expectations stabilize, the profitability of the pharmaceutical industry will gradually improve, and it is recommended to pay attention to the revaluation opportunities in the pharmaceutical sector

Sun-Novo

CanSinoBIO

CANSINOBIO

SANXING

Bank of China International: The Medical Insurance Bureau clarifies that centralized procurement is against involution, focusing on re-evaluation opportunities in the pharmaceutical sector

Weigao Orthopaedic released a draft of the 2025 restricted stock incentive plan, proposing to grant 7.2 million restricted shares, accounting for 1.80% of the company's total share capital. The initial grant will be 6.7 million shares, with 500,000 shares reserved, and the grant price is set at 13.89 yuan per share. The plan has a maximum validity period of 60 months

Weigao Orthopaedic plans to launch a restricted stock incentive plan in 2025

Weigao Orthopaedic released its 2024 annual report, with operating revenue of 1.453 billion yuan, a year-on-year increase of 13.18%; net profit attributable to the parent company was 224 million yuan, a year-on-year increase of 99.22%. The net profit excluding non-recurring gains and losses was 211 million yuan, a year-on-year increase of 95.44%. The basic earnings per share were 0.56 yuan, and it is proposed to distribute a cash dividend of 1.70 yuan for every 10 shares. The company has increased its market share and achieved performance growth by adjusting its business strategy and optimizing management

Weigao Orthopaedic released its 2024 annual performance, with a net profit attributable to the parent company of 224 million yuan, a year-on-year increase of 99.22%

According to the Zhitong Finance APP, Weigao Orthopaedic released its 2024 annual performance report. During the reporting period, the company achieved operating revenue of 1.452 billion yuan, a year-on-year increase of 13.14%; the net profit attributable to the parent company's owners was 222 million yuan, a year-on-year increase of 97.49%; the net profit attributable to the parent company's owners after deducting non-recurring gains and losses was 212 million yuan, a year-on-year increase of 96.29%; basic earnings per share were 0.55 yuan/share

Weigao Orthopaedic: Net profit for the year 2024 is 222 million yuan, a year-on-year increase of 97.49%

688333

Today, a total of 38 stocks in the A-share market experienced block trades, with a total transaction amount of 438 million yuan. BLT, Hengli Petrochemical, and Weigao Orthopaedic had the highest transaction amounts, at 65.5329 million yuan, 56.3101 million yuan, and 43.0287 million yuan, respectively. In terms of transaction prices, 10 stocks were traded at par, while 28 stocks were traded at a discount. Aifute-U, China Shipbuilding Emergency, and Pulian Software had the highest discount rates, at 22.35%, 20.98%, and 19.18%, respectively. Companies with the highest buying amounts from institutional special seats include Zhongke Feice, Xinzhisoft, and Yiheda

EFORT

HLSH

Newtouch

Sunline

MIDEA GROUP

CHINA HARZONE

Yiheda

Skyverse

Pansoft

Midea Group

Chase Sun

A-share block trading review: A total of 38 stocks had block trades, with a total transaction value of 438 million yuan

On the evening of January 21, Weigao Orthopaedic released its performance forecast for 2024. During the reporting period, the company expects to achieve a net profit attributable to the parent company of 200 million to 240 million yuan, a year-on-year increase of 78.07% to 113.68%

Weigao Orthopaedic expects a net profit increase of 78.07%-113.68% in 2024

WEIGAO GROUP expects its subsidiary WeigaoOrthopaedic to achieve a net profit attributable to the parent company of 200 million to 240 million yuan in 2024, a year-on-year increase of 78.07% to 113.68%. The company will actively implement the volume-based procurement policy, adjust its business strategy, optimize its product line and cost control, strengthen cooperation with medical institutions, and explore diversified market channels to increase market share and customer coverage. At the same time, WeigaoOrthopaedic will promote the development of new production lines and new markets to enhance its international brand influence

Canopus

Hn.F&A.Co.,Ltd.

MICROPORT

Xishan Science&Technology

WEIGAO GROUP: Weigao Orthopaedic expects the net profit attributable to the parent company in 2024 to be between 200 million and 240 million yuan, an increase of 78.07%-113.68% year-on-year

Wego Ortho(688161.SH)